ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

AGS-003 Increased Survival In Combination with Sunitinib

February 24, 2012

Investigator Initiated Clinical Research Gets More For Less Money, Carbone Contends

April 13, 1979

FDA, Companies Fail To Collect COI Forms, Report Says

January 16, 2009

ASCO, NCCN Develop Quality Measures For Cancer Care

August 25, 2006

In Brief: Boson Hotel Offers Free Rooms to Cancer Patients; Smoking Program Report Available

February 1, 1985

NCI Announces New Summer Training Awards

November 12, 1982